ServiceNow Demand Management for Life Sciences and Pharma

How Life Sciences Organizations Use Demand Management

Life sciences and pharmaceutical organizations have unique demand drivers: R&D projects for new drugs (multi-year, high investment), clinical trials (time-sensitive, regulatory milestones), manufacturing system improvements (must maintain compliance while optimizing), and regulatory compliance initiatives (mandatory to meet regulations). Demand Management must handle portfolio spanning years and prioritize across very different types of work.

Unlike software companies with monthly releases and rapid iteration, pharma operates on regulatory timelines (clinical trial phases spanning years, FDA review cycles) and manufacturing cycles (annual maintenance windows). Demand Management must support planning across these long timelines.

Regulatory Considerations in Demand Management

Clinical trial timelines are set by regulatory commitments, not by organizational capacity. If a clinical trial milestone is due in Q3, work must be prioritized to meet that deadline. Demand Management must support regulatory deadline management, not just capacity-based prioritization.

Manufacturing compliance work is mandatory: FDA inspections identify deficiencies that must be addressed. Compliance work cannot be deferred; it takes priority over discretionary improvements. Demand Management must flag compliance work as mandatory and ensure it has resources regardless of other demands.

Change control for validated systems: any change to systems used in regulated processes requires validation and approval. IT change demand is intertwined with system validation demand. Demand Management must track both and ensure validation happens before change deployment.

Key Stakeholder Groups

R&D leadership: sponsors drug development projects, defines research priorities aligned with pipeline strategy.

Clinical Operations: manages clinical trials, sets timelines for IT support per trial protocols. Regulatory deadlines are non-negotiable.

Manufacturing: operates production facilities, identifies improvements to efficiency and safety. Compliance work is mandatory; improvements are discretionary.

Quality and Compliance: identifies regulatory requirements, conducts audits, flags compliance gaps that must be addressed.

IT and Engineering: delivers IT and system changes, estimates capacity, manages competing demands across R&D, manufacturing, and compliance work.

Demand Prioritization Model for Pharma

Tier 1 (Mandatory): regulatory compliance, critical safety issues, clinical trial support. These are non-negotiable and take absolute priority. Examples: FDA warning letters, clinical trial milestone support, patient safety updates.

Tier 2 (Important): R&D project support, manufacturing optimization, operational efficiency. These are important but can be sequenced based on capacity and strategy alignment. Examples: new drug development projects, manufacturing line upgrades.

Tier 3 (Discretionary): technical debt, minor improvements, process optimization. These can be deferred if capacity is constrained. Examples: system consolidation, outdated software retirement, documentation improvements.

Within each tier, prioritize by strategic impact: does this advance the pipeline, improve profitability, reduce risk? Does this support a key strategic initiative?

Demand Management Workflow Specifics

Demand submission includes: business objective, tier (mandatory/important/discretionary), strategic alignment, estimated effort, timeline requirements (e.g., clinical trial milestones), regulatory implications. Requests without this information are sent back for clarification.

Quarterly demand review: portfolio managers, R&D, manufacturing, compliance, and IT meet to review new demands, adjust priorities, and allocate capacity. Clinical trial demands are reviewed for timeline conflicts. Compliance work is confirmed and scheduled.

Ongoing capacity management: track progress on approved demands. When work is blocked (waiting for external dependency, regulatory clarification), escalate. Maintain a reserve of capacity for urgent compliance or safety issues.

Planning for Long-Cycle Demands

Pharma demands often span years. A drug development project may require IT support over a multi-year period across discovery, preclinical, clinical trials, and post-approval phases. Demand Management must show multi-year planning and resource allocation.

Major IT initiatives (system upgrades, platform consolidations) can take a long time. These must be planned well in advance to avoid conflicts with critical R&D or manufacturing demands. Portfolio planning must balance short-term compliance work with long-term infrastructure needs.

Managing Uncertainty

Clinical trial timelines can shift due to regulatory delays, recruitment challenges, or data findings. Demand Management must be flexible: approved demands can be deferred if timelines change, or accelerated if regulatory paths narrow.

Regulatory requirements are sometimes surprising: new guidance documents can create new compliance demands. Maintain reserve capacity to address unexpected regulatory work.

Common Pitfalls

Over-committing to R&D projects and under-investing in compliance: compliance work is mandatory and non-negotiable. If all capacity is committed to optional work, compliance work gets delayed, creating regulatory risk.

Not planning for long clinical trial timelines: clinical trials can span many years. IT capacity must be reserved for the entire duration. Late discovery of capacity gaps causes trial delays and regulatory non-compliance.

Underestimating validation and compliance effort: system validation for regulated processes takes a meaningful portion longer than typical IT projects. Factor this into estimates.

Setting up intake so a compliance request cannot be scored away

The demand management overview introduces the intake process itself. What follows is the decision about which requests the scoring should see at all. When a demand process scores every request on the same scale, mandatory work loses. An inspection finding that requires a new control is measured against a proposed laboratory upgrade that promises faster throughput, and the upgrade often wins on the figures because its benefit is easier to quantify. The intake design should stop that from happening. Mandatory requests should enter through a route that does not compete on score, and only discretionary requests should be ranked against each other. The score then does the job it is good at, which is ordering choices that are genuinely optional.

Running a quarterly intake cycle that stays honest

A quarterly cycle usually depends more on fixed dates than on extra fields, and the strategic portfolio demand intake page covers the service.

1. Close the intake window on a fixed date, and return incomplete requests to the sponsor rather than accepting them into review.
2. Route each request by type, so mandatory items go to the compliance owner for confirmation and are not scored in the general list.
3. Score the discretionary requests against the agreed criteria, with each score traceable to a sentence the sponsor wrote.
4. Check the proposed plan for capacity clashes with multi-year programs before the board meets, not during it.
5. Record the decisions, the deferrals and the reasons, so the next cycle starts from what was actually decided.
6. Re-check approved items at the next cycle, because a program that slipped may need its reserved capacity released.

Where scoring models mislead in regulated portfolios

A scoring model with too many criteria often rewards whoever writes the most detail. The note on intake prioritization lists the factors a prioritization weighs. A model with a single criterion, often cost, favors whatever is cheapest. Keep the criteria few, write down what each one means, and decide the weights before anyone sees the scores. Do not let a sponsor adjust their own score after the discussion has started. Where a request touches a validated system, the validation effort should be scored as a cost, because it is often the largest unseen cost in a change to regulated software. Teams that skip this step often find their estimates running over plan.

Capacity that is reserved, not promised

Multi-year programs need capacity held for them across the whole portfolio plan, which is the planning layer the strategic portfolio management pages describe, not only within the quarter where the work starts. A trial or an upgrade that needs specialist validators in the middle years will fail if those people have been allocated to optional work in the meantime. The portfolio view should show reserved capacity as a separate line, so the board can see what it has already committed before it debates anything new.

Signals that the process is working

• Mandatory requests are confirmed within the same cycle they arrive, with no queue behind discretionary work.
• Approved items are delivered close to the period in which the sponsor said they would be, and when they slip, the board sees the cause.
• Requests returned as incomplete become shorter and more specific over successive cycles.
• Deferred items are reviewed rather than forgotten, and the reasons for deferral are visible to the sponsors.

When a full demand process is excessive

A small organization with a few projects a year gains little from a formal intake, although the roadmap prioritization work can be scaled down to suit, a scoring model and a quarterly board. A short list reviewed in one meeting, with mandatory items named and the rest agreed informally, may be the right design. The point of the process is to make trade-offs visible when there are enough of them to need it.

Questions portfolio owners ask about intake in regulated settings

Who decides that a request is mandatory?

The compliance or quality owner confirms that a regulatory or inspection source requires the work. The sponsor cannot make a request mandatory by describing it that way, and the board should be able to see the source document for any mandatory item.

How do you handle a request that is part compliance and part improvement?

Split it. The compliance element goes through the mandatory route with its own scope and deadline. The improvement element is scored separately, so that a good improvement is not hidden behind a required fix, and a required fix is not held back by a weak business case.

Should unused reserved capacity be released automatically?

Not automatically. Release it at a review point where the program owner confirms the milestone has moved, otherwise the capacity is lost to a program that is late.

Can the same intake serve R&D and manufacturing?

It can, if the routes differ by request type and the criteria are written for each area. Using one scoring scale for research bets and line changes can favor whichever area writes the better case.